Patents by Inventor Tomas Jandusik

Tomas Jandusik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2?3? cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
    Patent number: 11203610
    Abstract: The present disclosure relates to 2?3? cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 21, 2021
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
  • 3?3? cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
    Patent number: 10966999
    Abstract: Provided herein are the 3?3? cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 6, 2021
    Assignee: INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I.
    Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
  • 3'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN
    Publication number: 20190183917
    Abstract: Provided herein are the 3?3? cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 20, 2019
    Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
  • 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN
    Publication number: 20190185510
    Abstract: The present disclosure relates to 2?3? cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 20, 2019
    Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka
  • 2'2' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN
    Publication number: 20190185509
    Abstract: Provided herein are 2?2? cyclic phosphonate dinucleotides of formula (J), their pharmaceutically acceptable salts, hydrates or solvates, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, the dinucleotides can be used as adjuvants in vaccines.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 20, 2019
    Inventors: Gabriel Birkus, Ondrej Pav, Tomas Jandusik, Ivan Rosenberg, Radim Nencka